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OBJECTIVE: Crimean–Congo hemorrhagic fever is an acute viral hemorrhagic fever with a high mortality rate. Despite increas-
ing knowledge about hemorrhagic fever viruses, little is known about the pathogenesis of Crimean–Congo hemorrhagic fever. In 
this study, we measured serum adenosine deaminase and xanthine oxidase levels in Crimean–Congo hemorrhagic fever patients.
METHODS: Serum adenosine deaminase levels were measured with a sensitive colorimetric method described by Giusti and 
xanthine oxidase levels by the method of Worthington in 30 consecutive hospitalized patients (mean age 42.6 ± 21.0). Laboratory 
tests confirmed their diagnoses of Crimean–Congo hemorrhagic fever. Thirty-five subjects (mean age 42.9 ± 19.1) served as the 
control group.
RESULTS: There was a significant difference in adenosine deaminase and xanthine oxidase levels between cases and controls 
(p<0.05). However, neither adenosine deaminase nor xanthine oxidase levels varied with the severity of disease in the cases as-
sessed (p>0.05).
CONCLUSION: Adenosine deaminase and xanthine oxidase levels were increased in patients with Crimean–Congo hemorrhagic 
fever. Elevated serum xanthine oxidase activity in patients with Crimean–Congo hemorrhagic fever may be associated with reac-
tive oxygen species generated by the xanthine/xanthine oxidase system during inflammatory responses. In addition, elevated lipid 
peroxidation may contribute to cell damage and hemorrhage. The association of cell damage and hemorrhage with xanthine oxidase 
activity should be further investigated in large-scale studies.
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INTRODUCTION
Crimean–Congo hemorrhagic fever (CCHF) is an acute 
viral disease with a high mortality (3–30%) rate.1,2 It is 
caused by the CCHF virus (CCHFV). The virus belongs 
to the genus Nairovirus in the Bunyaviridae family. CCHF 
was first described in the 1940s, when more than 200 human 
cases occurred in the Crimean peninsula of the former Soviet 
Union, and it is now described in about 30 countries in 
Africa, Asia, Europe and the Middle East.3
CCHF, seen in approximately 30 countries worldwide, 
is a tick-borne disease with increasing importance and 
prevalence worldwide.4-11 Humans are infected through tick 
bites (especially Hyalomma species), by crushing infected 
ticks, or by contact with blood or tissue from acute-phase 
CCHF patients or viremic livestock. Most human cases 
occur in workers in the livestock and agriculture industries, 
slaughterhouses, and veterinary practices.12 Most patients 
(90%) with CCHF in Turkey have been farmers who were 
infected during outbreaks.2,4,5
There is a history of tick bite in approximately half 
(50–60%) of CCHF patients.2,4,5 The incidence of the 
disease is 20% among those who are infected.13 The course 
of CCHF infection has four distinct periods: incubation, 698
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prehemorrhagic, hemorrhagic, and convalescence.3 The 
incubation period for CCHF ranges from 2 to 12 days 
after the tick bite. This period ranges from 3 to 10 days 
in nosocomial cases.14,15 The prehemorrhagic period 
ranges from 1 to 7 days. The typical clinical symptoms 
during this period are sudden onset of fever (39–41°C), 
severe headache, myalgia, and dizziness.2-5,15,16 Additional 
symptoms include diarrhea, nausea and vomiting.1,15,16 
Cutaneous flushing or rash occur on the face, neck and 
chest during this period. Bradycardia and fever-pulse 
discordance are also observed.17 The hemorrhagic period 
develops rapidly and usually begins between the fifth 
and seventh days of disease.1 Patients may show signs 
of progressive hemorrhagic diathesis, such as petechiae, 
mucous membranes hemorrhage, conjunctival hemorrhage, 
nosebleed, hemoptysis, hematuria, hematemesis, and 
melena.1,17,18 Hepatomegaly and splenomegaly have been 
reported to occur in one-third of patients.3 The convalescence 
period begins in survivors approximately 10–20 days after 
the onset of illness. Patients usually require hospitalization 
for about 9–10 days.1,16 During the convalescence period, 
tachycardia, temporary complete hair loss, polyneuritis, 
difficulty in breathing, xerostomia, poor vision, loss of 
hearing, and loss of memory have been reported.3 Death 
usually occurs after 6–14 days of the disease. 
It has been reported that mononuclear phagocytes, 
hepatocytes, and endothelial cells are major targets of 
CCHF virus infection.19 Despite increasing knowledge 
about hemorrhagic fever viruses, little is known about the 
pathogenesis of CCHF.29
Adenosine deaminase (ADA; EC 3.5.4.4) is an enzyme 
that transforms, respectively, adenosine and deoxyadenosine 
to inosine and deoxyinosine, a stage of purine metabolism. In 
the ensuing reaction hypoxanthine is formed. The oxidation 
of hypoxanthine to xanthine and the oxidation of xanthine to 
uric acid are catalyzed by xanthine oxidase (XO; EC 1.1.3.22). 
ADA has two principal isoenzymes, ADA-1 and ADA-2. 
The low-molecular-weight ADA-1 is found in many tissues 
but predominantly in lymphocytes. The high-molecular-
weight ADA-2 is predominantly found in monocytes and 
macrophages.21,22 ADA-1 and ADA-2 play an important 
role in the function of immune cells. Increased serum/
plasma ADA activity, comprising both ADA-1 and ADA-2 
activity, has been used as a biochemical marker for infectious 
diseases.22-24 Increased serum ADA has been reported in 
infectious diseases such as viral and bacterial pneumonia, 
HIV infection, extra-pulmonary and pulmonary tuberculosis, 
visceral leishmaniasis, and mononucleosis.21,22,25
Xanthine oxidase is another intracellular enzyme that 
plays a role in nucleotide metabolism. It is involved in the 
catabolism of hypoxanthine and xanthine, which are formed 
during adenosine catabolism. The reactive oxygen species 
formed as a result of this reaction induce tissue damage in 
some viral diseases such as influenza.26
The aim of the present study was to investigate the serum 
levels of ADA-2 (the main source of ADA activity in the 
serum, which plays crucial roles in immune function) and 
xanthine oxidase (which increases tissue damage via the 
formation of free oxygen radicals) in CCHF patients and to 
compare the results with those obtained for healthy controls. 
We also determined whether the activities of these two 
intracellular enzymes were related to the severity of disease. 
MATERIALS AND METHODS
Study population
This prospective study was conducted between April 
1 and July 31, 2008 in Cumhuriyet University Hospital in 
Sivas, a city located in central Anatolia. The study protocol 
was approved by the Human Ethics Committee of the 
Cumhuriyet University Faculty of Medicine. Informed 
consent was obtained from each patient.
Thirty consecutive hospitalized patients, diagnosed 
with CCHF by laboratory tests, and 35 healthy volunteer 
adults, as controls who had no infections or immune 
system diseases such as rheumatoid arthritis, psoriasis and 
sarcoidosis, were included in this study. 
Blood collection
Venous blood samples were collected in tubes after an 
8-h fast and immediately stored at 4° C. Next, the serum 
was separated from the cells and fibrines by centrifugation 
at 1610xg for 10 min and stored in several aliquots at -80° 
C until assayed. A second blood sample from each patient 
was obtained and sent to the Virology Laboratory of Refik 
Saydam Hygiene Central Institute, Ankara, Turkey, for 
serologic and virologic analyses to confirm the diagnosis 
of CCHF. The definitive diagnosis of CCHF infection was 
based on typical clinical and epidemiological findings and 
the detection of CCHF virus-specific IgM by enzyme-linked 
immunosorbent assay (ELISA) or of genomic segments of 
the CCHF virus by reverse-transcription polymerase chain 
reaction (RT-PCR). All CCHF patients were classified into 
two groups in terms of disease severity (severe, non-severe), 
according to the predictive factors for fatal outcome criteria 
reported by Swanepoel and co-workers.15
Chemicals
Adenosine and hypoxanthine were supplied by Sigma-699
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Aldrich (Steinheim, Germany). All other chemicals used 
were obtained from Merck Darmstadt (Germany) and were 
of analytical grade.
Measurement of enzyme activities
ADA activity was estimated by the sensitive colorimetric 
method described by Giusti, and XO activity was determined 
by the method of Worthington.27,28 The assay results are 
expressed as specific activity (units per milligram of 
protein).
Statistical analysis
Parametric data are expressed as the mean ± standard 
deviation and categorical data as percentages. The Statistical 
Package for the Social Sciences (SPSS) version 14 for 
Windows (SPSS Inc., Chicago, IL, USA) was used for the 
statistical analysis. Parametric data were evaluated by the 
independent sample t-test and categorical data by the chi-
squared test. A p value ≤0.05 was considered as significant.
RESULTS
Thirty patients with CCHF and 35 control subjects were 
recruited for the study. Of the CCHF patients, 14 (47%) were 
male and 16 (53%) female, and the mean age was 42.6±21 
years. In the control group, twenty (57%) individuals 
were male and 15 (43%) were female, with a mean age of 
42.9±19.1 years. There were no significant differences in the 
age or sex ratio between patients with CCHF and controls 
(p>0.05).
All of the CCHF patients presented positive IgM and/or 
RT-PCR results for CCHF virus in the blood samples. Five 
(17%) of 30 patients had CCHFV-specific IgM antibodies, 
6/30 (20%) had a positive RT-PCR test for CCHFV, and 
19/30 (63%) were positive in both tests during the acute 
and/or convalescent phase of the disease. According to the 
severity score, 11 (37%) CCHF patients were classified as 
“severe”, whereas the remaining 19 (63%) patients were 
classified as “non-severe”. Only one patient with CCHF 
died during the hospitalization period. Table 1 shows the 
demographic, clinical and laboratory data for the patients 
and controls.
Serum ADA and XO levels in patients with CCHF were 
significantly higher than were those determined for the 
control group (p<0.05), as shown in Table 2. We found no 
significant difference in the serum ADA or XO level between 
severe and non-severe patients. Furthermore, no relationship 
was detected between XO and ALT levels in patients with 
CCHF (p>0.05).
Table 1- Demographic, clinical and laboratory data for 
patients with Crimean–Congo hemorrhagic fever and the 
control group.
CCHF
(n=30)
Control 
Group
(n=35)
 P
value
Mean age (year) 42.6 ± 21.0 42.9 ± 19.1 NS
Sex (female/male) 16/14 15/20 NS
FINDINGS n (%)
Most common symptoms
 Myalgia 
 Fever
18 (60)
26 (86.7)
Physical finding
 Fevera
 Conjunctival hyperemia 
 Maculopapular rash
 Petechia/ecchymosis
 Bleeding*
26 (86.7)
6 (20)
7 (23)
6 (20)
7 (23)
Laboratory findings
 Thrombocytopeniab
 Leukopeniac
 Elevated AST
 Elevated ALT
29 (96.7)
27 (90)
21 (70)
16 (53.3)
Risk factors for CCHF
 History of tick bite
 History of tick removal from animal
 No tick exposure
19 (63)
5 (17)
6 (20)
aArmpit, ≥38°C; bthrombocytopenia, platelet count <150x109; cleukopenia, 
leukocyte count <4x103. NS, non-significant; AST, aspartate aminotransfer-
ase; ALT, alanine aminotransferase; CCHF, Crimean–Congo hemorrhagic 
fever. *Epistaxis, hemoptysis, melena or hematemesis.
Table 2 - Serum ADA and XO levels in CCHF patients and 
controls.
CCHF
 (n=30)
Control 
Group
 (n=35)
p value
ADA specific activity
(U/mg protein)
1.16 ± 0,47 0.27 ± 0,06 0.000
XO specific activity
(U/mg protein)
2.23 ± 1,18 0.23 ± 0,19 0.000
Data are expressed as the mean ±standard deviation. CCHF, Crimean–Congo 
hemorrhagic fever; ADA, adenosine deaminase; XO, xanthine oxidase.
DISCUSSION
Patients infected with CCHFV were first reported in 
Turkey in 2002.4 Since 2002, CCHF outbreaks have been 
reported in rural areas of Turkey every year, especially in 
the spring and summer. To date, nearly 1800 confirmed 
CCHF cases have been reported in Turkey.29 Although the 
reported mortality rate for CCHF is 3–30%,1,2 the fatality 
rate in Turkey is 5%.29 Midilli et al. reported that all strains 
clustered within the same group with the Europe/Turkey 
isolates, despite their origins in eight different geographic 
areas of Turkey.30 It is not clear why those similar virus 700
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strains cause an asymptomatic clinical course in some 
patients but have a fatal outcome in others.
ADA deficiency is the major metabolic cause of severe 
combined immunodeficiency disease.31,32 ADA is important 
for the development of the immune system in humans. It 
seems to be associated with the differentiation of epithelial 
cells and monocytes and with neurotransmission.33 
Monocyte/macrophage activation by intracellular infection 
and inflammatory diseases leads to the release of ADA and 
elevated levels in the serum.34 Monocyte involvement in 
CCHF has been well described.19 However, no studies have 
reported the ADA/XO levels in patients with CCHF.
Increased serum ADA has been reported in infectious 
diseases such as viral and bacterial pneumonia, HIV 
infection, extra-pulmonary and pulmonary tuberculosis, 
visceral leishmaniasis, and mononucleosis.21,22,25
XO is another intracellular enzyme that plays a role in 
nucleotide metabolism. Vorbach and co-workers35 suggest 
that xanthine oxidoreductase (XOR) is central to the 
development and function of innate immunity. In purine 
catabolism, XOR catalyzes the oxidative hydroxylation 
of hypoxanthine to xanthine and subsequently of xanthine 
to uric acid. In this reaction, reactive oxygen species 
(ROS) such as superoxide anions (O2-), hydroxyl radicals 
(OH-) and hydrogen peroxide (H2O2) are produced. ROS 
may contribute to tissue damage in some viral infections 
such as influenza.9 XOR exists in two forms: xanthine 
dehydrogenase (XD; EC 1.1.1.204) and xanthine oxidase 
(XO; EC 1.1.3.22). In the normal physiological state, the XO 
activity in many tissues is very low, but it has been shown to 
increase dramatically following viral infection.26
There have been numerous recent studies on CCHF. 
These studies have focused on clinical and laboratory 
features or genetic characteristics.30,36-38 However, there are 
no reports concerning serum ADA and XO levels in CCHF 
patients. 
In the present study, we investigated serum ADA 
and serum XO activity in CCHF patients and controls. 
Serum ADA and XO levels in patients with CCHF were 
significantly higher than were those determined for the 
control group (p<0.05), whereas no significant association 
was observed between the serum ADA or XO level and the 
severity of disease in CCHF patients (p>0.05). 
An increased serum level of ADA has been reported in 
infectious diseases such as HIV infection, tuberculosis, and 
visceral leishmaniasis.22,25,39 However, the present study is 
the first to describe increased serum ADA and XO in CCHF 
patients.
Chittiprol and co-workers found high levels of plasma 
ADA in HIV-infected patients compared with controls, and 
this high level of ADA was associated with lymphocyte 
and monocyte infection by HIV. A similar mechanism of 
infection may occur in CCHF patients because monocytes 
can be infected by CCHFV.22
Whereas XO causes tissue damage by producing ROS, 
it can also protect against some infections by causing the 
production of uric acid and superoxide radicals.33,35 ROS 
generated by xanthine oxidase, such as superoxide anion 
radicals (O2-) and hydrogen peroxide (H2O2), may contribute 
to the tissue damage. The overproduction of these highly 
reactive oxygen metabolites can initiate lethal radical chain 
reactions involving the oxidation and damage of structures 
that are crucial for cellular integrity and survival. 
XOR is highly expressed in the liver for purine 
catabolism. Stirpe and co-workers reported that the level of 
total XOR was significantly higher in liver with virus-related 
cirrhosis but not in virus-negative cirrhosis, as compared 
to the controls.35,40,41 The level of XOR was increased in 
cirrhotic liver, in association with viral infection. This 
increase correlated with ALT, suggesting a relationship 
between XOR activity and the extent of liver injury caused 
by viral replication. The extent of oxidase activity seems 
to be correlated with tissue damage and consequent liver 
impairment. However, in our study, the XO level was highest 
in the patient group, and no relationship was observed 
between XO and ALT levels.
Tumor necrosis factor (TNF)-a and IL-6 are increased in 
CCHF infection.42,43 The inflammatory reaction results in the 
expression of various cytokines, and XOR is stimulated by 
interferon (IFN)-g, IFN-a, TNF-a, interleukin (IL)-1 and IL-
3; some of these factors also initiate the conversion from the 
XD to the XO form.35 Increased TNF-a or liver cell damage 
in CCHF patients may contribute to the increased XO level. 
However, this study was not designed to investigate the 
cause of the elevated ADA and XO levels in CCHF patients. 
Therefore, larger-scale studies are needed to explain this 
phenomenon. 
We hypothesize that the elevated serum XO activity in 
patients with CCHF is related to the free radicals generated 
by the xanthine/XO system. In addition, elevated lipid 
peroxidation may contribute to cell damage and hemorrhage. 
Therefore, serum ADA/XO activity, a relatively simple 
laboratory test parameter, particularly in the absence or in 
the event of delays in molecular procedures such as PCR 
and CCHF IgM detection, could supplement the laboratory 
approach for CCHF diagnosis and could be used to take 
preventive measures. 
In conclusion, we showed that ADA and XO levels were 
increased in patients with CCHF. However, we found no 
significant association between the serum ADA or XO level 
and the severity of disease in CCHF patients. 701
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